Table 2 Correlation between p16 expression and HPV status of all patients with head and neck cancers and those with oropharyngeal cancer
All patients N = 348 | OPSCC patients N = 64 | Non-OPSCC patients N = 284 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|  | HPV+ n = 14 (%) | HPV- n = 334 (%) | p-value |  | HPV+ n = 10 (%) | HPV- n = 54 (%) | p-value |  | HPV+ n = 4 (%) | HPV- n = 280 (%) | p-value |
p16+ n = 40 (%) | 9 (64) | 31 (9) | < 0.001 | p16+ n = 21 (%) | 8 (80) | 13 (24) | 0.001 | p16+ n = (%) | 1 (25) | 18 (6) | 0.243 |
p16- n = 308 (%) | 5 (36) | 303 (91) | p16- n = 43 (%) | 2 (20) | 41 (76) | p16- n = (%) | 3 (75) | 262 (94) | |||
p16 testing when using HPV DNA as a gold standard | |||||||||||
Sensitivity | 64% | Sensitivity | 80% | Sensitivity | 25% | ||||||
Specificity | 91% | Specificity | 76% | Specificity | 94% | ||||||
False positive | 9% | False positive | 24% | False positive | 6% | ||||||
False negative | 36% | False negative | 20% | False negative | 75% | ||||||
Positive predictive rate | 22% | Positive predictive rate | 38% | Positive predictive rate | 5% | ||||||
Negative predictive rate | 98% | Negative predictive rate | 95% | Negative predictive rate | 99% | ||||||
Discordant rate | 10% | Discordant rate | 23% | Discordant rate | 7% | ||||||